4.7 Article

Pharmacokinetic and pharmacodynamic properties of meropenem

期刊

CLINICAL INFECTIOUS DISEASES
卷 47, 期 -, 页码 S32-S40

出版社

OXFORD UNIV PRESS INC
DOI: 10.1086/590064

关键词

-

资金

  1. AstraZeneca
  2. Cubist
  3. Johnson Johnson
  4. Merck
  5. Pfizer
  6. Wyeth

向作者/读者索取更多资源

Pharmacokinetic and pharmacodynamic profiles of antibiotics are important in determining effective dosing regimens. Although minimum inhibitory concentration (MIC) data reflect microbial susceptibility to an antibiotic, they do not provide dosing information. The integration of pharmacokinetic and microbiological data, however, can be used to design rational dosing strategies. Meropenem is a broad-spectrum beta-lactam antibiotic that penetrates most body fluids and tissues rapidly after intravenous administration. Meropenem undergoes primarily renal elimination; therefore, dosage adjustment is required for patients with renal impairment. Meropenem is indicated for the treatment of complicated skin and skin-structure infections, complicated intra-abdominal infections, and bacterial meningitis. Meropenem has time-dependent bactericidal activity; thus, the percentage of time that free-drug concentrations are higher than the MIC (%T > MIC) characterizes the drug's pharmacodynamic profile (bactericidal target of similar to 40%T > MIC). Pharmacodynamic modeling can identify regimens with the greatest probability of attaining this target, and probabilities can be compared with clinical and microbiological responses in patients.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据